Impact of NSAIDS on mortality and the effect of preexisting coronary artery disease in US veterans

被引:25
作者
Lee, Todd A.
Bartle, Brian
Weiss, Kevin B.
机构
[1] Hines VA Hosp, Midwest Ctr Hlth Serv & Policy Res, Hines, IL 60141 USA
[2] Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL USA
[3] Northwestern Univ, Feinberg Sch Med, Div Gen Internal Med, Chicago, IL USA
关键词
osteoarthritis; nonsteroidal anti-inflammatory agent; mortality; coronary artery disease; pharmacoepidemiology;
D O I
10.1016/j.amjmed.2006.03.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Evidence indicates increased risk of cardiovascular events with certain nonsteroidal anti-inflammatory drug ( NSAID) use; however, less is known about NSAID use and mortality. In addition, it is unclear whether risks observed with NSAIDs are modified by coronary artery disease ( CAD). The association between NSAID exposure and mortality, cardiovascular, and cerebrovascular events was examined. METHODS: A nested case-control study in a cohort of 565,451 US veterans with a diagnosis of osteoarthritis was conducted. The cohort was divided into those with preexisting CAD ( 16,869 cases) and those without ( 11,912 cases). Up to 20 controls were selected for each case. RESULTS: The average age of participants was 69.8 years ( non-CAD) and 71.8 years ( CAD). Relative to no exposure, adjusted odds ratios for cardiovascular or cerebrovascular events for any NSAID were 1.14 ( 95% confidence interval [ CI], 1.08-1.21) in the non-CAD group and 1.18 ( 95% CI, 1.11-1.27) in the CAD group. Exposure to NSAIDs was associated with a decreased risk of all-cause mortality in both the non-CAD ( 0.72, 95% CI, 0.68-0.77) and CAD ( 0.79, 95% CI, 0.73-0.86) groups. CONCLUSIONS: As in previous reports, there was an increased risk of cardiovascular and cerebrovascular events for NSAIDs. However, NSAID exposure was associated with a reduced risk of death. This study raises important questions about NSAIDs in patients with osteoarthritis given that they seem to increase the risk of cardiovascular events but decrease overall mortality. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:98.e9 / 98.e16
页数:8
相关论文
共 27 条
  • [1] Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure
    Aw, TJ
    Haas, SJ
    Liew, D
    Krum, H
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (05) : 490 - 496
  • [2] Belton O, 2000, CIRCULATION, V102, P840
  • [3] Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
    Bombardier, C
    Laine, L
    Reicin, A
    Shapiro, D
    Burgos-Vargas, R
    Davis, B
    Day, R
    Ferraz, MB
    Hawkey, CJ
    Hochberg, MC
    Kvien, TK
    Schnitzer, TJ
    Weaver, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) : 1520 - 1528
  • [4] Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
    Bresalier, RS
    Sandler, RS
    Quan, H
    Bolognese, JA
    Oxenius, B
    Horgan, K
    Lines, C
    Riddell, R
    Morton, D
    Lanas, A
    Konstam, MA
    Baron, JA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) : 1092 - 1102
  • [5] COWPER DC, 2000, REHABILITATION OUTCO
  • [6] Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study
    Graham, DJ
    Campen, D
    Hui, R
    Spence, M
    Cheetham, C
    Levy, G
    Shoor, S
    Graham, D
    [J]. LANCET, 2005, 365 (9458) : 475 - 481
  • [7] Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis
    Hippisley-Cox, J
    Coupland, C
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7504): : 1366 - 1369
  • [8] Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
    Juni, P
    Nartey, L
    Reichenbach, S
    Sterchi, R
    Dieppe, PA
    Egger, M
    [J]. LANCET, 2004, 364 (9450) : 2021 - 2029
  • [9] Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction
    Kimmel, SE
    Berlin, JA
    Reilly, M
    Jaskowiak, J
    Kishel, L
    Chittams, J
    Strom, BL
    [J]. ANNALS OF INTERNAL MEDICINE, 2005, 142 (03) : 157 - 164
  • [10] Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
    Konstam, MA
    Weir, MR
    Reicin, A
    Shapiro, D
    Sperling, RS
    Barr, E
    Gertz, BJ
    [J]. CIRCULATION, 2001, 104 (19) : 2280 - 2288